Natus Medical Inc. (BABY) Short Interest Update
Natus Medical Inc. (NASDAQ:BABY) was the recipient of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 1,260,195 shares, a decrease of 25.7% from the October 31st total of 1,696,657 shares. Based on an average daily volume of 272,843 shares, the days-to-cover ratio is currently 4.6 days. Currently, 4.0% of the shares of the company are sold short.
In other news, CFO Jonathan Kennedy sold 30,276 shares of the stock in a transaction that occurred on Tuesday, October 25th. The stock was sold at an average price of $41.40, for a total value of $1,253,426.40. Following the completion of the sale, the chief financial officer now directly owns 91,351 shares of the company’s stock, valued at $3,781,931.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider James B. Hawkins acquired 10,000 shares of Natus Medical stock in a transaction dated Wednesday, September 28th. The stock was acquired at an average cost of $38.48 per share, with a total value of $384,800.00. Following the completion of the transaction, the insider now directly owns 459,725 shares of the company’s stock, valued at approximately $17,690,218. The disclosure for this purchase can be found here. Company insiders own 4.80% of the company’s stock.
A number of large investors have recently made changes to their positions in the stock. Acrospire Investment Management LLC raised its position in Natus Medical by 39.1% in the second quarter. Acrospire Investment Management LLC now owns 2,844 shares of the company’s stock valued at $108,000 after buying an additional 800 shares during the period. BlackRock Inc. raised its position in Natus Medical by 36.0% in the second quarter. BlackRock Inc. now owns 3,096 shares of the company’s stock valued at $117,000 after buying an additional 820 shares during the period. Tower Research Capital LLC TRC raised its position in Natus Medical by 72.6% in the third quarter. Tower Research Capital LLC TRC now owns 3,327 shares of the company’s stock valued at $131,000 after buying an additional 1,399 shares during the period. Quantbot Technologies LP bought a new position in Natus Medical during the third quarter valued at $156,000. Finally, PineBridge Investments L.P. raised its position in Natus Medical by 3.7% in the second quarter. PineBridge Investments L.P. now owns 4,200 shares of the company’s stock valued at $159,000 after buying an additional 149 shares during the period. 84.01% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have recently weighed in on the company. Raymond James Financial Inc. raised Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price objective for the company in a research report on Tuesday, September 13th. Zacks Investment Research cut Natus Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, September 28th. Finally, Benchmark Co. assumed coverage on Natus Medical in a research report on Tuesday, October 4th. They issued a “buy” rating and a $55.00 price objective for the company.
Natus Medical (NASDAQ:BABY) opened at 42.05 on Wednesday. The company has a market capitalization of $1.36 billion, a PE ratio of 34.19 and a beta of 1.16. The company has a 50-day moving average price of $40.74 and a 200 day moving average price of $38.82. Natus Medical has a 12 month low of $29.54 and a 12 month high of $51.05.
Natus Medical (NASDAQ:BABY) last announced its earnings results on Wednesday, October 19th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.34 by $0.05. Natus Medical had a return on equity of 13.53% and a net margin of 10.89%. The business had revenue of $90.90 million for the quarter, compared to analyst estimates of $89.94 million. During the same quarter last year, the firm earned $0.39 EPS. Natus Medical’s revenue for the quarter was down 3.9% compared to the same quarter last year. On average, equities research analysts forecast that Natus Medical will post $1.64 EPS for the current fiscal year.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Stock Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related stocks with our FREE daily email newsletter.